« Back   View All - CTP Profiles

Sam Schulman

M.D., FRCPC(C) 

Professor, Division of Hematology and Thromboembolism, Department of Medicine, McMaster University
Associate Professor, Medicine, Karolinska Institute, Stockholm, Sweden
Director, Clinical Thromboembolism Program Hamilton Health Sciences

schulms@mcmaster.ca

Sam Schulman graduated from Karolinska Institute, Stockholm, Sweden in 1977 and became a specialist in Internal Medicine in 1984, with subspecialties in Hematology and in Coagulation in 1985.  That year he also received his Dr Med Sc with the thesis : "Studies on the Medical Treatment of Deep Vein Thrombosis". He has worked within the field of coagulation disorders continuously since 1984, worked as a consultant at the national Hemophilia Center at Tel Hashomer, Israel 1992-1996 and was director of the Hemophilia Treatment Center in Stockholm 1996-2004. His major research activities have been clinical studies in venous thromboembolism, including several randomized trials and in hemophilia and its complications. He is currently involved in trials with new antithrombotic agents, such as the oral thrombin inhibitors. He has been a member of the Executive Committee of the World Federation of Hemophilia (2000-2004) and was chairman of the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of ISTH 2005-2008. Dr. Schulman is associate professor in Internal Medicine at Karolinska Institute and since September 2004 also professor in Medicine at McMaster University. He is Director of the Thrombosis Service at HHS-General Hospital in Hamilton and Director of the Clinical Thromboembolism Program of McMaster University.

Dr. Schulman is president elect for the XXV Congress of the International Society of Thrombosis and Haemostasis, Toronto 2015.

Team Members

Administrative Assistant: Joan Murphy
Manager Anticoagulant Clinic: Marlene Robinson, Clinical; Donna Carter, administrative
Clinical Trials Nurses: Michelle Zondag, Lisa Rudd-Scott
Acute Care Nurses: Thelma Mendoza, Jennifer Delaney, Joyce Colletti, Deborah Magier, Ellen Nicholson, Christine Cockhill

Selected Publications

   1. Schulman S, Kearon C et al. Definition of major bleeding in clinical investigations of medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-4.

   2. The PERSIST INVESTIGATORS (Büller HR, Cohen AT, Lensing AWA, Monreal M, Prins MH, Schulman S, Lassen MR, van Amsterdam RGM). A novel long-acting synthetic factor Xa inhibitor, (SanOrg 34006) to replace warfarin for secondary prevention in deep vein thrombosis: a phase II evaluation. J Thromb Haemost 2004; 2: 47-53.

   3. Schulman S, Wåhlander K, Lundström T, Clason SB, Eriksson H; THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med. 2003 Oct 30;349(18):1713-21.

   4. Schulman S. Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003; 349: 675-83.

   5. Eriksson H, Wåhlander K, Gustafsson D, Welin L, Frison L, Schulman S. A randomised, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003; 1: 41 -7.

   6. Schulman S, Lindmarker P and the DURAC Trial Study Group. Incidence of cancer after secondary prophylaxis against venous thromboembolism with warfarin. N Engl J Med 2000; 342: 1953-8.

   7. Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund S-G, Nordlander S, Lärfars G, Leijd B, Linder O, Loogna E and the Duration of Anticoagulation Trial Study Group. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336: 393-8.

   8. Schulman S, Rhedin A-S, Lindmarker P, Carlsson A, Lärfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H, Viering S, Nordlander S, Leijd B, Jönsson K-Å, Hjorth M, Linder O, Boberg J and The DURAC Trial Study Group. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-5.

   9. Hedner U, Glazer S, Pingel K, Alberts KA, Blombäck M, Schulman S, Johnsson H. Successful use of recombinant factor VIIa in a patient with severe haemophilia A during synovectomy. Lancet 1988; 2: 1193

‚Äč